FDA clears TuHURA's Phase 3 trial for cancer therapy IFx-2.0

TuHURA Biosciences (HURA) announced the FDA lifted the partial clinical hold on its Phase 3 trial for IFx-2.0, an adjunctive therapy for advanced Merkel cell carcinoma, allowing the trial to commence in late June 2025. The trial, under an SPA agreement, will assess IFx-2.0's efficacy alongside Keytruda, with a primary endpoint of Overall Response Rate; resolution of the hold unlocks an additional $2.23 million from a prior PIPE financing. Despite a recent stock decline, analysts project significant upside, and the company's healthy liquidity position, along with a FAIR financial health score, supports ongoing development efforts, including a planned merger with Kineta, Inc.

Analysis

TuHURA Biosciences (NASDAQ:HURA) has achieved a significant milestone as the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold on its Phase 3 trial for IFx-2.0, a potential adjunctive therapy for advanced and metastatic Merkel cell carcinoma (MCC). This pivotal development enables the trial, operating under a Special Protocol Assessment (SPA) agreement with the FDA, to initiate in late June 2025. The study will enroll 118 patients to evaluate IFx-2.0 in conjunction with Keytruda®, targeting Overall Response Rate (ORR) as the primary endpoint, which could pave the way for accelerated approval, and Progression Free Survival (PFS) as a key secondary endpoint. Concurrently, this resolution secures an additional $2.23 million from a $12.5 million PIPE financing. Despite its stock declining nearly 10% over the past week and a market capitalization of $123 million, TuHURA demonstrates a healthy liquidity position, evidenced by a current ratio of 3.0 and a FAIR financial health score from InvestingPro. Analyst outlook is notably positive, with price targets spanning $9.25 to $15.00; H.C. Wainwright recently reiterated a Buy rating and a $12 price target, projecting the company's year-end cash of $12.7 million will sustain operations into late 2025, notwithstanding a wider-than-expected net loss in 2024. This positive regulatory news, combined with a recent $15.5 million capital raise and an anticipated merger with Kineta, Inc., bolsters TuHURA's strategy to advance its immuno-oncology pipeline; this pipeline includes its lead candidate IFx-2.0, the ongoing Phase 1b/2a trial for IFx-Hu2.0 with results anticipated by late 2025 or early 2026, and the advancement of Kineta’s VISTA inhibiting antibody.

Key Decisions for Investors

• Investors should recognize the FDA's decision to lift the clinical hold as a key de-risking event for IFx-2.0, positioning the upcoming Phase 3 trial, under an SPA agreement, as a critical near-term value inflection point.
• The disparity between the recent ~10% stock price decline and the strong analyst price targets ($9.25-$15.00), alongside a current ratio of 3.0 and a cash runway into late 2025, may indicate a valuation opportunity, though investors must weigh this against the inherent clinical development risks and the company's 2024 net loss.
• Monitoring the Phase 3 trial's ORR and PFS outcomes, the successful execution of the Kineta merger and subsequent pipeline integration, and prudent management of the company's $12.7 million cash reserve will be crucial for assessing TuHURA's ongoing investment thesis.